Suppr超能文献

一种新型细胞培养模型揭示了乙型肝炎和丙型肝炎病毒合并感染时的病毒干扰。

A novel cell culture model reveals the viral interference during hepatitis B and C virus coinfection.

机构信息

Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.

Reproductive Medical Center, Obstetrics and Gynecology Department, Peking University Third Hospital, 49 North Garden Road, Haidian Distinct, Beijing, 100191, China.

出版信息

Antiviral Res. 2021 May;189:105061. doi: 10.1016/j.antiviral.2021.105061. Epub 2021 Mar 9.

Abstract

Coinfection of hepatitis B virus (HBV) and hepatitis C virus (HCV) may result in severe liver disease and frequent progression to cirrhosis and hepatocellular carcinoma. Clinical evidence suggests that HBV replication is suppressed by replicating HCV and often rebounds after treatment with drugs against HCV. Thus, a highly efficient cell culture system permissive for HBV/HCV would facilitate investigation on the interaction and pathogenesis after coinfection. Here we reported a robust HBV/HCV coinfection cell culture model by overexpressing human sodium-taurocholate cotransporting polypeptide (NTCP), CD81 and Mir122 into HepG2 cells and investigated interactions between HBV and HCV. In this system, HepG2-NTCP/CD81/Mir122 cells not only supported robust infection and replication of HBV and HCV, but also allowed HBV/HCV coinfection in the single cell level. Our result showed cells with replicating HBV still supported HCV infection. However, HBV replication was suppressed by HCV through the inhibition of HBV core promoter and S promoter II activity, and this inhibition was attenuated by the interferon alpha (IFNα) treatment, suggesting HCV influence on HBV at transcriptional level. Coinfection of HBV/HCV in this system did not block IFN stimulated genes expression. Inhibition of HCV by direct-acting antiviral drugs restored HBV replication and expression of viral genes. Conclusions: HepG2-NTCP/CD81/Mir122 fully supports HBV/HCV coinfection, replication and interaction. This novel cell model offers a platform to advance our understanding of the molecular details of the interaction, pathogenesis and outcomes of HBV/HCV coinfection.

摘要

乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)的合并感染可导致严重的肝脏疾病,并经常进展为肝硬化和肝细胞癌。临床证据表明,HBV 复制受到复制 HCV 的抑制,并且在用抗 HCV 药物治疗后经常反弹。因此,允许 HBV/HCV 复制的高效细胞培养系统将有助于研究合并感染后的相互作用和发病机制。在这里,我们通过过表达人牛磺胆酸钠共转运多肽(NTCP)、CD81 和 Mir122 到 HepG2 细胞中,报道了一种强大的 HBV/HCV 合并感染细胞培养模型,并研究了 HBV 和 HCV 之间的相互作用。在该系统中,HepG2-NTCP/CD81/Mir122 细胞不仅支持 HBV 和 HCV 的强大感染和复制,而且还允许在单细胞水平上进行 HBV/HCV 合并感染。我们的结果表明,具有复制性的 HBV 仍支持 HCV 感染。然而,HCV 通过抑制 HBV 核心启动子和 S 启动子 II 活性抑制了 HBV 复制,这种抑制作用被干扰素α(IFNα)治疗减弱,表明 HCV 在转录水平上对 HBV 的影响。该系统中 HBV/HCV 的合并感染并没有阻断 IFN 刺激基因的表达。直接作用抗病毒药物抑制 HCV 恢复了 HBV 复制和病毒基因的表达。结论:HepG2-NTCP/CD81/Mir122 完全支持 HBV/HCV 合并感染、复制和相互作用。该新型细胞模型为深入了解 HBV/HCV 合并感染的分子细节、发病机制和结局提供了一个平台。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验